Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Early-stage nodular lymphocyte predominant Hodgkin lymphoma: Disease characteristics, treatment pattern, and long-term outcomes from a tertiary care cancer institute in India

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJayant Sastri GodaAKAnkita KanojaASAlok Shetty

Discussion

Loading...

Member takes

Overview

Observational study reports high progression free survival in early-stage lymphoma, suggesting effective treatment strategies.

Key Points

  • This research aims to evaluate disease characteristics and treatment outcomes for early-stage nodular lymphocyte predominant Hodgkin lymphoma.
  • Included consecutive patients diagnosed with stage I–II NLPHL from 2010 to 2022.
  • Categorized treatment modalities as radiotherapy, chemotherapy, combined modality treatment, or observation.
  • Evaluated survival outcomes using Kaplan–Meier method and assessed prognostic scoring systems.
  • 112 early-stage NLPHL patients were analyzed with a median age of 31 years.
  • 8-year progression free survival was 91% and overall survival was 98%.
  • Treatment included radiotherapy in 51% and combined modality treatment in 43%.

Cite This Study

Goda et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2e1https://doi.org/10.1182/blood-2025-5404
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India2025
  2. 2Real world epidemiological trends in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), England 2014-2021: Preliminary data from the uncover Study group2025
  3. 3Clinical profile and treatment outcomes of lymphoma patients: A retrospective cohort study.2026
  4. 4Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP2025
  5. 5Academic cancer programs deliver improved long-term survival in nodular lymphocyte predominant Hodgkin lymphoma: Insights from 7,000+ United States patients2025